# Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)

> **NCT02463305** · EARLY_PHASE1 · WITHDRAWN · sponsor: **University of Colorado, Denver**

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Creatine monohydrate
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02463305
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-08
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** inability to enroll
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02463305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02463305, "Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02463305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*